At stake is who gets the keys to the most powerful AI tools and what happens when those keys are turned: national security, commercial advantage and patient safety all sit at the center of the debate over access to frontier artificial intelligence models.
Anthropic’s Mythos and OpenAI: contrasting gatekeeping strategies
On this week’s ISMG Editors’ Panel, the editors laid out a sharp contrast in how two leading developers approach access to frontier AI cybersecurity models. The conversation identified differing strategies at Anthropic and OpenAI in granting access to advanced AI cybersecurity models, and framed those choices as a balancing act among safety, competitive strategy and control over emerging capabilities.
The panel specifically called out Anthropic’s Mythos as an example of a frontier model at the heart of the debate. Editors said the different access approaches underscore competing priorities: restricting distribution to limit misuse versus broader access to spread defensive benefits and shape industry norms.
Washington’s divide: the White House weighing security against risk
Panelists described a growing policy divide in Washington over access to powerful frontier AI cybersecurity models. According to the discussion, the White House is weighing possible national security advantages against the risks that wider deployment could create if safeguards are insufficient.
That tension — between potential operational gains for defense and intelligence actors and the possibility of harm from inadequate controls — was presented as central to the current policy debate. Editors framed the question as not only technical, but political: who decides how far access should go, and on what timetable?
FDA pilots AI-supported real-time clinical trials
The panel also turned to healthcare, reporting that the U.S. Food and Drug Administration is piloting AI-supported real-time clinical trials. The editors said the FDA’s effort aims to accelerate drug development by improving efficiency, patient monitoring and decision-making in early-stage trials.
Panelists highlighted the pilot as a concrete example of regulators experimenting with AI inside regulated processes, noting the FDA’s interest in leveraging real-time analytics and support to shorten development cycles while maintaining oversight.
What this means for technologists, policymakers, and healthcare leaders
- Technologists and security teams will continue to grapple with trade-offs between open access that speeds innovation and restricted access intended to limit misuse; the panel portrayed those trade-offs as central to vendor strategies at companies like Anthropic and OpenAI.
- Policymakers and the White House are weighing national security gains against the risk of broader deployment without adequate safeguards; the debate in Washington reflects a split between those focused on immediate operational advantages and those urging conservative controls.
- Healthcare leaders and regulators should expect continued experimentation, exemplified by the FDA’s pilot of AI-supported real-time clinical trials aimed at improving efficiency, monitoring and decision-making in early-stage drug testing.
Panel composition and continuity
The ISMG Editors’ Panel that aired the discussion identified its participants as Anna Delaney, executive director, productions; Marianne Kolbasuk McGee, executive editor, HealthcareInfoSecurity; Michael Novinson, executive editor, ISMG Business; and Chris Riotta, managing editor, GovInfoSecurity. The panel runs weekly; recent editions included an April 24 conversation on the push for AI innovation and its fallout and a May 1 edition on North Korea’s latest crypto heists.
The editors portrayed the current moment as one where technical capability, corporate strategy and government policy are colliding. The decisions made now — by vendors about access, by the White House about permissible use, and by the FDA about experimental deployment in clinical settings — will shape who controls frontier AI tools and where those tools are first applied. That convergence of interests, the panel suggested, will produce policy fights and operational experiments in equal measure.
Read the original ISMG Editors: The Battle Over Access to Frontier AI Models
